03-09-2026 16:57 via drugs.com

Focal Therapy Use Remains Uncommon in Nonmetastatic Prostate Cancer

THURSDAY, Sept. 3, 2026-- For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use is defined as inappropriate in about half of recipients, according to a research letter published...
Read more »

Pharmaceutical Industry news



Alcohol-Attributable Cancer Mortality Has Increased Significantly in the U.S.
FDA Approves First-in-Class Drug for Polycythemia Vera
Maintaining Physical Activity Tied to Better Quality of Life With Multiple Sclerosis
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
About 1 in 20 Hospitalized U.S. Adults With Firearm Injuries Develop Bacterial Infections
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage
Causes, Outcomes of Traumatic Brain Injury Identified Worldwide
FDA Clears Blood Test for Alzheimer Disease
Time-Restricted Eating May Help Patients With Type 1 Diabetes
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women
ESC: Silent Atherosclerosis Present in 57.1 Percent of Adults Aged 18 to 70
ESC: Atorvastatin Lowers Cardiovascular Event Risk in Older Adults Without Clinical CVD
Updated Recommendations Address Medications to Prevent Migraine in Adults
Desktop versie